About the Company
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $QTRX News
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics ...
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix Corporation QTRX, a player in ultra-sensitive research products and diagnostics, achieved a significant milestone when the FDA granted a Breakthrough Device designation to its Simoa ...
Quanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic Potential
Begin your TipRanks Premium journey today. Quanterix (QTRX) Company Description: Quanterix Corp. is a life sciences company, which develops ultra-sensitive digital immunoassay platform that advances ...
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their Estimates
It's been a good week for Quanterix Corporation ( NASDAQ:QTRX ) shareholders, because the company has just released ...
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ...
CryoPort Q4 2023 Earnings Preview
CryoPort is set to announce their Q4 earnings results, with an estimated EPS of -$0.30 and a revenue estimate of $58.39M.
Loading the latest forecasts...